Bio-Connect
EIDD-2801 [2349386-89-4]

EIDD-2801 [2349386-89-4]

Research Use Only
AG-CR1-3733
AdipoGen Life Sciences
CAS Number2349386-89-4
Product group Chemicals
Estimated Purity>98%
Molecular Weight329.3
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    EIDD-2801 [2349386-89-4]
  • Delivery Days Customer
    10
  • CAS Number
    2349386-89-4
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C13H19N3O7
  • Molecular Weight
    329.3
  • Scientific Description
    Chemical. CAS: 2349386-89-4. Formula: C13H19N3O7. MW: 329.3. EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4-hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broad-spectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment. - EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4-hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. This mechanism of inhibition of viral replication is also known as lethal mutagenesis. The broad-spectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment. Treatment of SARS-CoV-2 infection with EIDD-2801 completely suppressed virus transmission within 24 hours in ferrets.
  • SMILES
    O=C(N(C=C/1)[C@@H]2O[C@H](COC(C(C)C)=O)[C@@H](O)[C@H]2O)NC1=N\O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200